Home / Peptides / Retatrutide
Investigational — not FDA approved

Retatrutide

The “triple G” agonist with striking early data — and why that isn’t the same as approval

Investigational drug

Retatrutide is still in clinical trials. It is not approved by the FDA, its long-term safety is not established, and any product sold as “retatrutide” outside a trial is unregulated. This page is educational, not medical advice.

Mechanism

GLP-1 + GIP + glucagon

FDA Status

Phase 3

Developer

Eli Lilly

What retatrutide is

Retatrutide (development code LY3437943) is an investigational once-weekly injectable that activates three receptors: GLP-1, GIP, and — unlike semaglutide or tirzepatide — the glucagon receptor. The glucagon arm is thought to increase energy expenditure on top of the appetite and glucose effects of the incretin pathways, which is the mechanistic reason interest in it is so high. It is being developed by Eli Lilly and, as of now, exists only as a trial drug.

What the early data showed

Phase 2 obesity trial

  • Population: 338 adults with obesity, without diabetes
  • Duration: 48 weeks
  • Result: at the highest dose (12 mg), mean weight reduction of about −24%, in a clear dose-dependent pattern

Source: Jastreboff AM, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." N Engl J Med. 2023.

A separate Phase 2 trial in type 2 diabetes reported meaningful A1c and weight reductions as well. These results are why retatrutide gets described as potentially best-in-class — but they come from mid-stage trials in a few hundred people, not the large, long outcome trials that approval requires.

Why “promising” is not “proven”

  • Phase 2 measures short-term weight and glucose change; it does not establish long-term safety or cardiovascular benefit.
  • The glucagon component raises questions — for example about heart rate and glucose control — that larger trials are specifically designed to answer.
  • Gastrointestinal side effects were dose-dependent, consistent with the drug class.
  • Effects seen in a screened trial population may not generalize to everyone.

Where it is now

Retatrutide has moved into the Phase 3 TRIUMPH program, a set of large trials spanning obesity, type 2 diabetes, and related conditions. Those readouts — not social-media before-and-afters — are what will determine whether and how it gets approved. Until then, the honest status is: genuinely promising, genuinely unproven, and not something available as a legitimate prescription.

Related reading: the retatrutide development timeline and the latest Phase 3 topline results.

Following the trial pipeline? Jabbit is where people privately track GLP-1 and next-generation protocols.

Download on App Store